Nano Mobile Healthcare (VNTH) Stock Price

Nano Mobile Healthcare, Inc. generates revenue through the development and sale of detection devices based on patented NASA technology. The company licenses its products from Nanobeak, which holds the original NASA patent, and focuses on disease screening and drug detection applications. Its primary customers are healthcare providers and pharmaceutical companies seeking advanced diagnostic tools. The firm's products integrate nano-electronics, bio-informatics, and wireless technology to deliver innovative screening solutions. The company's business model relies on licensing agreements with Nanobeak for the NASA-developed technology, which is then adapted for medical use. By leveraging this patented technology, Nano Mobile Healthcare targets healthcare institutions and pharmaceutical firms requiring precise diagnostic capabilities. The firm's product line centers on disease and drug screening, positioning it within the medical device sector without specifying additional market segments. Revenue streams are derived from the sale of detection devices and related services, with no mention of subscription models or additional product lines. The company's focus remains on the convergence of nano-electronics, bio-informatics, and wireless technology for medical applications, ensuring alignment with its core technological foundation.